alexa Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Cardiology

Cardiology

Journal of Hypertension: Open Access

Author(s): Robles NR, Romero B, FernandezCarbonero E, SnchezCasado E, Cubero JJ

Abstract Share this page

Abstract INTRODUCTION: There are no adequate head-to-head comparisons of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) in type 2 diabetic patients in spite of some interesting attempts. Furthermore, there are no adequate studies about the effects of ACE inhibitors in type 2 diabetic patients, who are the great majority of diabetic individuals. This study has retrospectively compared the effects of ACE inhibitors and ARBs used to treat diabetic nephropathy in a group of type 2 diabetic subjects. DESIGN AND METHODS: Patients (n=154) were treated with ACE inhibitors (mean age 59.5+/-13.3 years, 52.6\% were male). Eighty-five patients had been treated with ARBs from 1999 until now (mean age 62.6+/-10.9 years, 56.0\% were male, differences not significant). Kaplan-Meier survival analysis was used to calculate survival before reaching end-stage renal disease (ESRD) (glomerular filtration < 15 ml/min, stage V of renal disease as defined by KDOQI clinical guidelines) or starting renal replacement therapy. Only patients treated for more than six months were included in the survival analysis. Comparison of survival was made at three, five and seven years after starting treatment. RESULTS: Pre-ESRD survival was 91.9\% at three years, 81.6\% at five years and 61.9\% at seven years of follow-up for patients treated with ACE inhibitors. For patients treated with ARBs, pre-ESRD survival was 95.3\% at three years, 82.1\% at five years and 78.2\% at seven years of follow-up (p=0.02, log-rank test). At 36 months, the comparative odds ratio for having started renal replacement therapy or reaching end-stage renal failure was 0.246 (95\% confidence interval 0.114-0.531, p<0.001 for chi-square and likelihood ratio tests). The risk for the ARB cohort was 0.682 (95\% confidence interval 0.578-0.804), meanwhile for ACE inhibitor patients it was 2.768 (95\% confidence interval 1.481-5.172). CONCLUSIONS: The effects of ACE inhibitors and ARBs seem to be different, favouring the use of ARBs. These results may have been influenced by the different circumstances when each kind of drug was indicated, since ARBs were used with the specific recommendations for control of blood pressure in diabetic patients. An earlier referral of these patients may also have had some effect on these results. The need for a well-designed prospective study on type 2 diabetic patients with heavy proteinuria is warranted. This article was published in J Renin Angiotensin Aldosterone Syst and referenced in Journal of Hypertension: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

  • Shoude Jin
    Mechanisms of Chronic obstructive pulmonary disease and airway smooth muscle remodeling: the potential roles of Abhd2
    PDF Version
  • Alsayed Alnahal
    Urinary netrin-1 predict early ischemic acute kidney injury after cardiopulmonary bypass
    PPT Version | PDF Version
  • Ping Yang
    Chronic obstructive pulmonary disease (COPD) complicating early-stage lung cancer (LC)
    PDF Version
  • Gunilla Lindqvist
    Chronic obstructive pulmonary disease: A study of the relationship between patients’ feeling of guilt due to their belief of the disease being self inflicted
    PDF Version
  • Roger Mark Engel
    The effect of including manual therapy in the management of mild chronic obstructive pulmonary disease – a randomized controlled trial
    PDF Version
  • Ekambaram Umapathy
    An association between vasoactive agents and etiology of hypertension and obesity in HIV patients in Mthatha, South Africa
    PPT Version | PDF Version
  • Roberto Antonio Flores
    Control and monitoring of patients with Hypertension in the Community of the National University of Santiago del Estero, Argentina
    PPT Version | PDF Version
  • Rupal Patel Mansukhani
    Correlation of Medication Therapy in Chronic Obstructive Pulmonary Disease(COPD) Patients with 30-day Readmission Rates
    PPT Version | PDF Version
  • Myriam Isnard-Rouchon
    Cardiovascular risk factors evolution during 6 months intra dialytic aerobic cycling program in hemodaylais patients: Hypertension, hyperlipidemia, hemoglobin stability and cardiovascular morbidity in hemodaylais patients
    PPT Version | PDF Version
  • Hadeel Faisal Gad
    In-vitro analysis of cytokines responses of visceral leishmaniasis and pulmonary tuberculosis patients to homologous and heterologous antigen stimulation
    PPT Version | PDF Version
  • Xin Wang
    IL17 Pathway Involves Moderating Pulmonary Hypertension, a common complication of COPD, in Statins Therapy in Smoking Rats
    PPT Version | PDF Version
  • Joanna Trojanek
    Metalloproteinases and their inhibitors gene expression profiles in leukocytes of primary hypertension (PH), non-alcoholic fatty liver disease (NAFLD), and obese children
    PPT Version | PDF Version
  • Paloma Manea
    COMPARISON BETWEEN HS-C REACTIVE PROTEIN AND MICROALBUMINURIA LEVELS FOR THE PROGNOSIS OF RENOVASCULAR HYPERTENSION
    PPT Version | PDF Version
  • Renuka R. Nair
    RELATIONSHIP BETWEEN OXIDATIVE STRESS AND ENERGY METABOLISM IN HYPERTENSION INDUCED CARDIAC REMODELING
    PDF Version
  • Edward Rojas
    Targeting Hypertension in Patients with the Cardio-Renal Metabolic Syndrome
    PDF Version

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords